Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article by a group of Romanian researchers published in October this year may have some controversial implications — so we want to be very clear that we don’t think too much should be read into it unless their data can be replicated by others.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, bicalutamide, effect, orientation, sexual | Leave a Comment »
Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH [...]
Filed under: Management, Treatment | Tagged: antiandrogen, bicalutamide, high-dose, hormone, second-line, therapy | Leave a Comment »
While it has never been categorically proven that adding an oral antiandrogen like flutamide or bicalutamide (Casodex) to injections of LHRH agonists (e.g., leuprolide actetate) improves overall patient survival, there had been little doubt in people’s minds that giving an antiandrogen for a week or two before a first LHRH agonist injection prevented the problem [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antiandrogen, flare, LHRH agonist, testosterone | 1 Comment »
Today’s important news reports address: 5- and 7-year survival data following iodine-125 permanent implant brachytherapy Risks associated with low levels of lymphocyte apoptosis in patients receiving radiation therapy Stiffening of the large arteries in men receiving antiandrogen therapy The status of the toremifene and denosumab applications for approval for marketing in the USA
Filed under: Drugs in development, Management, Treatment | Tagged: antiandrogen, apoptosis, approval, arteries, brachytherapy, denosumab, iodine-125, long-term, lymphocyte, radiation therapy, stiffening, survival, toremifene, toxicity | Leave a Comment »
Newly published studies today include data on: Risk for patients with prostate atypia on biopsy having a subsequent diagnosis of prostate cancer Patterns of failure of patients treated with brachytherapy for localized disease Quality of life following differing types of radiotherapy Second-line antiandrogen therapy following initial failure of a first-line antiandrogen in advanced prostate cancer [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, antiandrogen, atypia, bicalutamide, brachytherapy, cancer, depression, fatigue, flutamide, irritability, mood, prostate, quality of life, radiotherapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site